je.st
news
Tag: cancer
These tapeworms spontaneously transformed into a cancer inside their victim
2015-11-06 16:08:38| Extremetech
A puzzling case from the Annals of Medicine presents a challenge to our understanding of cells and organisms. Tapeworms inside the lung of an immuno-compromised patient have turned themselves into a cancer.
Tags: their
inside
cancer
victim
WHO Cancer Report Hurts Agency's Credibility
2015-11-06 01:00:00| ThePigSite - Industry News
CANADA - A food scientist with the University of Manitoba suggests a recent report by the cancer agency of the World Health Organization has hurt its credibility, writes Bruce Cochrane.
Tags: report
cancer
credibility
hurts
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
2015-11-03 12:58:00| Merck.com - Product News
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSKs investigational immunotherapy GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. Language: English Contact: MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
potential
treatment
combination
Processed and red meat classified as cancer risk
2015-11-02 17:56:00| National Hog Farmer
By P. Scott Shearer, Bockorny Group, Washington, D.C. Group asks USDA to keep processed meat off school menus World Health Organization classifies meat as cancer risk, then modifies statement to say meat still has a place in people's diets. read more
Tags: red
risk
cancer
processed
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Advanced Colorectal Cancer
2015-11-02 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
food
administration
drug
Sites : [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] next »